These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25164620)

  • 1. A multicenter long-term study of imatinib treatment for Japanese patients with unresectable or recurrent gastrointestinal stromal tumors.
    Ogata K; Mochiki E; Ojima H; Haga N; Fukuchi M; Aihara R; Ando H; Uchida N; Toyomasu Y; Suzuki M; Kimura A; Kogure N; Yokobori T; Ohno T; Kuwano H
    J Surg Oncol; 2014 Dec; 110(8):942-6. PubMed ID: 25164620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
    Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
    Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Imatinib Treatment for Patients with Unresectable or Recurrent Gastrointestinal Stromal Tumors.
    Ogata K; Kimura A; Nakazawa N; Suzuki M; Yanoma T; Ubukata Y; Iwamatsu K; Kogure N; Yanai M; Kuwano H
    Digestion; 2018; 97(1):20-25. PubMed ID: 29393163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy of imatinib for treatment of metastatic GIST.
    Patel S
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):277-86. PubMed ID: 23503753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib.
    Tielen R; Verhoef C; van Coevorden F; Gelderblom H; Sleijfer S; Hartgrink HH; Bonenkamp JJ; van der Graaf WT; de Wilt JH
    Eur J Surg Oncol; 2013 Feb; 39(2):150-5. PubMed ID: 23084087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].
    Wan DS; Wu XJ; Pan ZZ; Zhou ZW; Chen G; Li LR; Lu ZH; Ding PR
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(43):3064-7. PubMed ID: 17288838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses.
    Park SJ; Ryu MH; Ryoo BY; Park YS; Sohn BS; Kim HJ; Kim CW; Kim KH; Yu CS; Yook JH; Kim BS; Kang YK
    Ann Surg Oncol; 2014 Dec; 21(13):4211-7. PubMed ID: 24980089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience.
    Rutkowski P; Gronchi A; Hohenberger P; Bonvalot S; Schöffski P; Bauer S; Fumagalli E; Nyckowski P; Nguyen BP; Kerst JM; Fiore M; Bylina E; Hoiczyk M; Cats A; Casali PG; Le Cesne A; Treckmann J; Stoeckle E; de Wilt JH; Sleijfer S; Tielen R; van der Graaf W; Verhoef C; van Coevorden F
    Ann Surg Oncol; 2013 Sep; 20(9):2937-43. PubMed ID: 23760587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
    Du CY; Zhou Y; Song C; Wang YP; Jie ZG; He YL; Liang XB; Cao H; Yan ZS; Shi YQ
    Eur J Cancer; 2014 Jul; 50(10):1772-1778. PubMed ID: 24768330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
    Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].
    Shen L; Jin ML
    Zhonghua Zhong Liu Za Zhi; 2004 Nov; 26(11):697-9. PubMed ID: 15777512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
    Zhu J; Yang Y; Zhou L; Jiang M; Hou M
    BMC Cancer; 2010 May; 10():199. PubMed ID: 20465813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of surgical cytoreduction prior to imatinib therapy on the prognosis of patients with advanced GIST.
    An HJ; Ryu MH; Ryoo BY; Sohn BS; Kim KH; Oh ST; Yu CS; Yook JH; Kim BS; Kang YK
    Ann Surg Oncol; 2013 Dec; 20(13):4212-8. PubMed ID: 24052319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
    Majer IM; Gelderblom H; van den Hout WB; Gray E; Verheggen BG
    J Med Econ; 2013 Sep; 16(9):1106-19. PubMed ID: 23808902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib.
    Jakob J; Mussi C; Ronellenfitsch U; Wardelmann E; Negri T; Gronchi A; Hohenberger P
    Ann Surg Oncol; 2013 Feb; 20(2):586-92. PubMed ID: 22965573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
    Kang YK; Kang BW; Im SA; Lee JL; Park SR; Kang WK; Chang HM; Kim TW; Oh DY; Jung KH; Ryu MH
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):43-51. PubMed ID: 23053257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor.
    Shen C; Chen H; Yin Y; Chen J; Zhang B; Chen Z; Chen J
    Clinics (Sao Paulo); 2014 Nov; 69(11):758-62. PubMed ID: 25518034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy observation on imatinib adjuvant therapy with longer duration in patients with gastrointestinal stromal at intermediate or high risk of recurrence].
    Li J; Dang YZ; Gao J; Shen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):216-20. PubMed ID: 23536338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective observational study of imatinib therapy in Japanese patients with advanced gastrointestinal stromal tumors: long-term follow-up and second malignancy.
    Kanda T; Ishikawa T; Hirota S; Yajima K; Kosugi S; Ohashi M; Suzuki S; Mashima Y; Ajioka Y; Hatakeyama K
    Jpn J Clin Oncol; 2012 Jul; 42(7):578-85. PubMed ID: 22523393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.
    Andtbacka RH; Ng CS; Scaife CL; Cormier JN; Hunt KK; Pisters PW; Pollock RE; Benjamin RS; Burgess MA; Chen LL; Trent J; Patel SR; Raymond K; Feig BW
    Ann Surg Oncol; 2007 Jan; 14(1):14-24. PubMed ID: 17072676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.